BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-142@catalystbrief.girapphe.com
DTSTAMP:20261118T181545Z
LAST-MODIFIED:20261118T181545Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Adverum Biotechnologies\, Inc. — Ixo-vec [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Efficacy and Safety Study of Ixober
 ogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related 
 Macular Degeneration.\nSource: https://clinicaltrials.gov/study/NCT0685657
 7\nhttps://catalystbrief.girapphe.com/e/142?lang=en\nNot investment advice
 . Dates may change.
URL:https://catalystbrief.girapphe.com/e/142?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
